MaxCyte price target raised to $7 from $6 at BTIG

BTIG raised the firm’s price target on MaxCyte (MXCT) to $7 from $6 and keeps a Buy rating on the shares. MaxCyte, and its large customer Vertex Pharmaceuticals (VRTX), are likely four weeks away from securing the first ever CRISPR-approved cell and gene therapy, which would be a landmark achievement in biopharma, the analyst tells investors in a research note. The firm thinks FDA approval is highly likely following that Ad Comm meeting that “went well.”